Aroa Biosurgery Reports Strong Sales Growth in 2025

Aroa Biosurgery Ltd (AU:ARX) has released an update.

Aroa Biosurgery Limited reported a significant 25% increase in product sales for the first half of the 2025 financial year, driven by the Myriad and Ovitex product lines. The company’s Myriad sales surged 45%, contributing to 38% of total product sales and achieving an impressive gross margin of 87%. With strong sales productivity and a solid cash reserve, Aroa remains on track for positive cash flows and continued growth.

For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.